Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAWN HASSLER

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1427122928
CMS profile
291581
Location
SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$64,622.36

246 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAWN HASSLER

NPI 1427122928 · CMS profile ID 291581

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427122928?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAWN HASSLER, NPI 1427122928, CMS profile ID 291581. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427122928?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHAWN HASSLER, NPI 1427122928, CMS profile ID 291581. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427122928?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHAWN HASSLER, NPI 1427122928, CMS profile ID 291581, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 246 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1427122928?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

246 matching records · $64,622.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 246 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 246.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ViiV Healthcare Company $2.3710/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189582500 CMS
EMD Serono, Inc. $26.1410/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236888140 CMS
Merck Sharp & Dohme LLC $27.9910/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238200398 CMS
ViiV Healthcare Company $124.8710/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189541913 CMS
Gilead Sciences, Inc. $4,560.0010/06/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351032 CMS
Theratechnologies Inc. $46.2310/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226373771 CMS
Novo Nordisk Inc $25.6810/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188801993 CMS
TOLMAR, INC. $23.2410/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237023292 CMS
ABBVIE INC. $11.9810/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202018278 CMS
Napo Pharmaceuticals Inc $150.0010/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223619314 CMS
EMD Serono, Inc. $11.0009/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236881797 CMS
ABBVIE INC. $33.8209/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202018276 CMS
Gilead Sciences, Inc. $172.1009/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234370232 CMS
Gilead Sciences, Inc. $28.5209/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373649 CMS
Gilead Sciences, Inc. $56.0109/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412652 CMS
Gilead Sciences, Inc. $56.0109/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412654 CMS
Gilead Sciences, Inc. $55.9909/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412730 CMS
Gilead Sciences, Inc. $55.9909/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234412732 CMS
Gilead Sciences, Inc. $960.9609/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234363913 CMS
Gilead Sciences, Inc. $307.1709/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234368124 CMS
Napo Pharmaceuticals Inc $24.8309/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223619294 CMS
Merck Sharp & Dohme LLC $31.6009/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238080917 CMS
EMD Serono, Inc. $38.6609/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236888640 CMS
Gilead Sciences, Inc. $24.7109/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234477366 CMS
Gilead Sciences, Inc. $19.1009/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234537765 CMS
ViiV Healthcare Company $32.8309/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189523198 CMS
ViiV Healthcare Company $1.2509/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189580510 CMS
Gilead Sciences, Inc. $20.5309/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234522867 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $27.3909/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241333284 CMS
Theratechnologies Inc. $0.6009/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226373765 CMS
Theratechnologies Inc. $13.1409/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226373776 CMS
ABBVIE INC. $29.1309/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202018274 CMS
Antares Pharma, Inc. $21.3909/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235887544 CMS
Lilly USA, LLC $27.0009/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186905424 CMS
Gilead Sciences, Inc. $32.4208/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234426462 CMS
Gilead Sciences, Inc. $6.4508/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234597155 CMS
Merck Sharp & Dohme LLC $34.0408/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238261913 CMS
ViiV Healthcare Company $5.5008/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189556234 CMS
ViiV Healthcare Company $26.6508/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189567695 CMS
ViiV Healthcare Company $2,600.0008/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189613158 CMS
Axsome Therapeutics, Inc. $29.1108/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235468549 CMS
Novo Nordisk Inc $20.4908/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188233563 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.5208/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223929322 CMS
ViiV Healthcare Company $1,625.0008/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189512598 CMS
Theratechnologies Inc. $38.5608/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226373760 CMS
ViiV Healthcare Company $23.7408/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189509636 CMS
ViiV Healthcare Company $14.1908/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189564536 CMS
Gilead Sciences, Inc. $26.8908/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234459270 CMS
EMD Serono, Inc. $34.4608/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236909549 CMS
Gilead Sciences, Inc. $2,450.0008/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234356398 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $107,860.28 320
PY2020 $31,069.79 96
PY2021 $31,002.22 102
PY2022 $54,312.10 157
PY2023 $79,317.32 195
PY2024 $64,995.55 213
PY2025 $64,622.36 246

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $614,061.16 41
PY2024 Principal investigator $664,192.94 45
PY2023 Recipient $129,441.26 17
PY2023 Principal investigator $493,285.87 528
PY2022 Recipient $269,721.23 12
PY2022 Principal investigator $613,934.62 604
PY2021 Principal investigator $310,629.48 59
PY2020 Principal investigator $648,447.65 102
PY2019 Principal investigator $554,637.09 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
STUDYOPS INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534215
Principal investigator 1 Merck Sharp & Dohme LLC $19,022.88 12/31/2025 Non-covered Recipient Entity
Optimus Medical
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929425
Principal investigator 1 Merck Sharp & Dohme LLC $274.40 12/31/2025 Non-covered Recipient Entity
Optimus Medical
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929427
Principal investigator 1 Gilead Sciences, Inc. $811.00 12/16/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220597
Principal investigator 1 Merck Sharp & Dohme LLC $19,829.00 12/15/2025 Non-covered Recipient Entity
Optimus Medical
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1232929203
Principal investigator 1 ABBVIE INC. $24,337.50 12/04/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527706
Principal investigator 1 Gilead Sciences, Inc. $4,696.00 11/18/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220589
Principal investigator 1 Gilead Sciences, Inc. $9,500.00 11/12/2025 Non-covered Recipient Entity
STUDYOPS, INC.
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215264
Principal investigator 1 Gilead Sciences, Inc. $4,321.00 11/12/2025 Non-covered Recipient Entity
STUDYOPS, INC.
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215274
Principal investigator 1 Gilead Sciences, Inc. $4,621.00 11/12/2025 Non-covered Recipient Entity
STUDYOPS, INC.
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215283
Principal investigator 1 Gilead Sciences, Inc. $4,621.00 11/12/2025 Non-covered Recipient Entity
STUDYOPS, INC.
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215291
Principal investigator 1 Gilead Sciences, Inc. $9,000.00 11/12/2025 Non-covered Recipient Entity
STUDYOPS, INC.
Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People: Qualitative Insights Into Social and Behavioral Contexts No dispute reported 06/30/2026 1229215301
Principal investigator 1 ABBVIE INC. $35,445.00 11/05/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522773
Principal investigator 1 ABBVIE INC. $2,137.50 11/04/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202521007
Principal investigator 1 ABBVIE INC. $13,260.00 10/09/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514937
Principal investigator 1 ABBVIE INC. $16,385.86 10/09/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202515069
Principal investigator 1 Gilead Sciences, Inc. $1,959.00 09/16/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220579
Principal investigator 1 ABBVIE INC. $19,507.50 09/04/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509412
Principal investigator 1 ABBVIE INC. $21,267.27 09/03/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202507861
Principal investigator 1 Gilead Sciences, Inc. $5,877.00 08/19/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220568
Principal investigator 1 ABBVIE INC. $24,030.00 08/06/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503075
Principal investigator 1 ABBVIE INC. $23,831.76 08/05/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202501762
Principal investigator 1 Gilead Sciences, Inc. $3,397.00 07/22/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220560
Principal investigator 1 ABBVIE INC. $22,950.00 07/02/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494727
Principal investigator 1 ABBVIE INC. $32,965.06 07/02/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202494729
Principal investigator 1 SANOFI US SERVICES INC. $12,630.00 06/27/2025 Non-covered Recipient Entity
Studyops Inc
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226101530
Principal investigator 1 Gilead Sciences, Inc. $1,715.00 06/17/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220552
Principal investigator 1 ABBVIE INC. $11,231.92 06/03/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202488019
Principal investigator 1 ABBVIE INC. $23,250.00 06/03/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488021
Principal investigator 1 Gilead Sciences, Inc. $3,430.00 05/20/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220543
Principal investigator 1 ABBVIE INC. $2,940.00 05/07/2025 Non-covered Recipient Entity
STUDYOPS INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483261
Principal investigator 1 ABBVIE INC. $30,833.78 05/06/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202481753
Principal investigator 1 Gilead Sciences, Inc. $3,726.00 04/22/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220535
Principal investigator 1 ABBVIE INC. $39,238.45 04/03/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202473720
Principal investigator 1 Gilead Sciences, Inc. $7,176.00 03/18/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220527
Principal investigator 1 ABBVIE INC. $49,434.91 03/07/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202459537
Principal investigator 1 ABBVIE INC. $24,330.00 03/07/2025 Non-covered Recipient Entity
STUDYOPS INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202459542
Principal investigator 1 Gilead Sciences, Inc. $1,351.00 02/19/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220519
Principal investigator 1 ABBVIE INC. $7,260.00 02/06/2025 Non-covered Recipient Entity
STUDYOPS INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202449145
Principal investigator 1 ABBVIE INC. $68,188.37 02/06/2025 Non-covered Recipient Entity
OPTIMUS MEDICAL GROUP
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202449160
Principal investigator 1 Gilead Sciences, Inc. $2,679.00 01/22/2025 Non-covered Recipient Entity
STUDYOPS, INC.
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229220509